Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co. shares MRK, +0.11% rose 0.8% premarket Thursday, after the drug company beat estimates for the fourth quarter after chalking up more than $950 million in sales from its COVID-19 antiviral molnupiravir. The company posted net income of $3.820 billion, or $1.51 a share, for the quarter, after a loss of $2.617 billion, or $1.03 a share, in the year-earlier period.

Merck tops Q4 estimates as COVID antiviral chalks up $952 million of sales

Merck & Co said on Wednesday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir.

Merck sees 2022 sales up nearly 20%, mostly on molnupiravir

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results

Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results

Bank of America

Kinross Gold

These income stocks are screaming bargains following the recent market sell-off.

3 Dividend Stocks That Can Make You Richer in February (and Beyond)

Merck is scheduled to report its Q4 2021 results on Thursday, Feb 3. We expect MRK stock to trend higher in the near term due to an upbeat Q4, with revenue and earnings expected to be comfortably above the consensus estimates, driven by contribution from its Covid-19 antiviral pill, and continued.

Will Merck Stock Rise After Its Q4 Results?

ConocoPhillips

Honeywell

U.S. equity markets opened mixed on Tuesday. By mid-morning, the Dow Jones industrials still clung to a fractional gain, while the S&P 500 and the Nasdaq continued sinking.

Earnings Previews: ConocoPhillips, Honeywell, Merck

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.

Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?

Chevron

These two large-cap value stocks should markedly outperform the broader market this month.

2 Incredibly Cheap Value Stocks to Buy in February

Amgen

Boeing

Disney

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Just because a company is a massive household name doesn't always mean investors should jump in after its stock takes a sizable dip.

Are the Dow's Worst-Performing Stocks of 2021 Ready to Rebound in 2022?

Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.

Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use

Merck & Co Inc MRK and its partner Ridgeback Biotherapeutics said six lab studies showed their investigational oral COVID-19 drug molnupiravir was active against the omicron variant. [ALERT[ Matt Maley just released his latest pick with an upside of over 100% in 2 years.

Merck's COVID-19 Pill works Against Omicron, Lab Studies Show

Merck & Co. Inc. MRK, +1.82% and partner Ridgeback Biotherapeutics said Friday that data from six preclinical studies of its molnupiravir COVID-19 pill showed "consisent antiviral activity" against the omicron variant of the coronavirus that causes COVID-19. The preclinical studies were conducted independently in Belgium, Czech Republic, Germany, Poland, the Netherlands and the U.S. Molnupiravir is currently authorized for use in 10 countries, including the U.S., the U.K. and Japan.

Merck, Ridgeback says COVID-19 pill molnupiravir shows antiviral activity against omicron variant

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant

Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies

Renal cell carcinoma is the most common type of kidney cancer; about nine out of 10 kidney cancer diagnoses are RCCs.

Merck's Keytruda Wins European Approval For Post-Surgery Kidney Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves Merck's KEYTRUDA as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

Carnival

Clorox

Ford Motor Company

General Dynamics

Norwegian Cruise Line

Nielsen Hlds

ServiceNow

Twitter

The three major U.S. equities indexes again closed lower on Tuesday. The Nasdaq closed 2.3% lower, the Dow Jones industrials dipped by 0.2% and the S&P 500 lost 1.2%.

Wednesday's Premarket: 5 S&P 500 Winners, 5 Losers

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Second-Quarter 2022 Dividend

Merck Announces Second-Quarter 2022 Dividend

Merck's (MRK) new drug application for gefapixant to treat refractory chronic cough or unexplained chronic cough fails to secure approval from the FDA. Meanwhile, the drug secures approval in Japan.

Merck's (MRK) Chronic Cough Drug Gets CRL From FDA

Gilead Sciences

Eli Lilly

Pfizer

Regeneron Pharmaceuticals

Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.

Large Cap Pharma, Biotech Stocks Down on Regulatory Updates

Britain must find a further 6,000 people to trial Merck's (Coronavirus) COVID-19 antiviral pill to gauge how best to roll it out on a larger scale, Reuters reported.  The Medicines and Healthcare Products Regulatory Agency (MHRA) approved the pill, named molnupiravir, in November, but the Government is trying to establish the best way to use the drug in a largely vaccinated population after being trialed via a national study on unvaccinated citizens.

Britain needs 6,000 more volunteers to take Merck's COVID-19 pill mainstream

Salesforce

Visa

Walgreens

The 125-year-old Dow Jones Industrial Average is home to these four exceptional growth and value stocks.

These 4 Dow Stocks Are Screaming Buys in 2022

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19, reported Reuters. The pill is approved in Britain for use in people with mild to moderate COVID-19.

Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

Merck (NYSE: MRK) said that the FDA issued a CRL about gefapixant. These are the details.

Merck (MRK): FDA Requests More Information About Gefapixant

AbbVie

CVS Health

Not only is the price right for these three healthcare stocks, but they all offer revenue growth along with an above-average dividend.

3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150

Shares of Merck & Co. Inc. MRK, -0.95% gained 0.4% in premarket trading on Monday after the company said the Food and Drug Administration requested additional information about its experimental cough treatment. The regulator issued a complete response letter asking for more data about the measurement of efficacy for gefapixant, Merck's investigational therapy for refractory or unexplained chronic cough.

News for Merck Stock (MRK)